Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Holding ARWR?
Track your performance easily
ARWR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.05 - $39.83
Previous Close$18.71
Volume75.31K
Average Volume (3M)1.06M
Market Cap
$2.27B
Enterprise Value$2.07B
Total Cash (Recent Filing)$367.27M
Total Debt (Recent Filing)$118.09M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 26, 2024EPS Estimate
-$0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.65
Shares Outstanding124,315,274
10 Day Avg. Volume1,185,687
30 Day Avg. Volume1,061,147
Standard Deviation0.19
R-Squared0.06
Alpha-0.00715
Financial Highlights & Ratios
Price to Book (P/B)7.03
Price to Sales (P/S)117.68
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue105.43
Enterprise Value/Gross Profit8.60
Enterprise Value/Ebitda-4.08
Forecast
1Y Price Target
$42.56Price Target Upside131.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Approval And EfficacyThe positive data from the Phase 3 PALISADE trial supports the potential approval of plozasiran for treating familial chylomicronemia syndrome.
Drug Safety And EfficacyPlozasiran was well-tolerated with a favorable safety profile, showing significant reductions in key triglyceride levels and other cholesterol metrics.
Financial Performance And StrategyArrowhead Pharmaceuticals announced securing $500M strategic financing facility with flexible 7-year repayment structure, which supports its aggressive pipeline expansion.
Bears Say
Financial PerformanceThe equity sell-off was driven by relatively expensive debt financing coinciding with higher than expected R&D spend.
Operational ConcernsInvestor focus remains on operational expenditure growth, debt burden, and greater clarity on the ongoing cardiovascular outcomes trial.
Product EfficacyPlozasiran treatment led to a rise in LDL cholesterol, which is not a desired treatment outcome even if TGs decrease.
---
Ownership Overview
4.46% Insiders
20.64% Mutual Funds
23.11% Other Institutional Investors
26.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $17.05 and its highest was $39.83 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 26, 2024 which is in 5 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.529 by -$0.851.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -$0.97.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,315,280 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.529. Following the earnings report the stock price went down -9.439%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 95M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.56 (131.43% Upside)
$42.56 (131.43% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 907.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.25%
12-Months-Change
Fundamentals
Return on Equity
-154.92%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
ARWR Earnings Call
Q3 2024
0:00 / 0:00
---
ARWR Stock 12 Month Forecast
Average Price Target
$42.56
▲(131.43% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Voyager Therapeutics
―
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
19/37 ratings generated profit
1 Year Average Return
+32.94%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 51.35% of your transactions generating a profit, with an average return of +32.94% per trade.
---